0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessGuohong Han, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Osamu Yokosuka, Olivier Rosmorduc, В. В. Бредер, René Gerolami, Gianluca Masi, Paul J. Ross, Shukui Qin, Tianqiang Song, Jean‐Pierre Bronowicki, Isabelle Ollivier‐Hourmand, Masatoshi Kudo, Marie-Aude LeBerre, Annette Baumhauer, Gerold Meinhardt, Jordi Bruix (2018). 4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment. , 29(4), DOI: https://doi.org/10.1016/j.jvir.2018.01.420.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2018
Authors
20
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1016/j.jvir.2018.01.420
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
